Health Catalyst, Inc. filings document operating results, material-event reporting, and governance changes for a Nasdaq-listed healthcare data and analytics company. Recent Form 8-K disclosures include quarterly and annual financial results, preliminary unaudited financial updates, and press-release exhibits furnished under results-of-operations items.
The company’s filings also cover board appointments, executive transitions, compensatory arrangements, transition and separation agreements, executive severance-plan references, workforce-reduction disclosures, and related governance matters. These records provide formal disclosure around Health Catalyst’s management structure, financial condition, and material corporate events.
Nelson Steven H reported acquisition or exercise transactions in this Form 4 filing.
Health Catalyst, Inc. director Steven H. Nelson received an equity grant of 154,808 restricted stock units of common stock as compensation. The units were granted at no cash cost under the company’s 2019 Stock Option and Incentive Plan and are subject to multi‑year vesting.
According to the award terms, 33.33% of the RSUs will vest on May 1, 2027. The remaining 66.67% will then vest in two equal annual installments, so Nelson’s ability to receive all underlying shares depends on continued service through these future vesting dates.
Health Catalyst, Inc. director Steven H. Nelson filed an initial ownership report on Form 3. This filing establishes his status as a director and confirms that, as of this report, there are no buy, sell, or other insider transactions disclosed in the data provided.
Health Catalyst, Inc. officer Benjamin Albert reported a proposed sale of 310 common shares, with an approximate sale date of May 1, 2026 and an aggregate market value of $416.95. The shares are listed as restricted stock acquired from Health Catalyst as compensation on May 1, 2026. The form also lists earlier restricted-stock sales of 13,304 shares on February 26, 2026, 4,966 shares on March 2, 2026, and 70,455 shares on March 10, 2026.
Health Catalyst, Inc. CEO Albert Benjamin reported routine equity compensation activity. On April 29, 2026, he received an award of 1,124 performance-based restricted units (PRSUs) based on 2025 performance, with each PRSU representing a contingent right to one common share.
On May 1, 2026, 310 common shares were sold at $1.345 per share to cover tax withholding obligations tied to vesting of restricted stock units under the company’s equity plans. This sell-to-cover transaction was mandated by the company and was not a discretionary trade. Following these transactions, Benjamin directly holds 1,458,792 common shares.
Health Catalyst, Inc. filed Amendment No. 1 to its 2025 annual report to add detailed Part III information on directors, executive officers, corporate governance, and compensation. The filing reflects leadership changes, including Benjamin Albert becoming Chief Executive Officer and Daniel Burton’s retirement, plus departures of the Chief Commercial Officer and Chief Operating Officer.
Executive pay remains heavily performance-based, with about 87% of 2025 target CEO compensation and 82% for other named officers at risk through bonuses and equity. Annual bonuses for 2025 were delivered entirely in performance RSUs tied to client outcomes, growth, and Adjusted EBITDA; only 39% of these PRSUs vested after many growth targets fell below threshold.
Long-term PRSUs use three-year performance periods based on total shareholder return relative to the Russell 3000, revenue growth, and Adjusted EBITDA margin. For 2025, strong profitability drove Adjusted EBITDA of $41.4 million, above the $40.0 million threshold but below the $45.0 million target, while revenue growth and TSR underperformed, leading to partial vesting on performance awards.
Health Catalyst, Inc. announced that its board has appointed Steve Nelson, Executive Vice President and President of Aetna, to its Board of Directors, effective May 1, 2026. He will serve as a Class II director until the 2027 annual meeting, filling a new seventh board seat.
The board size will later return to six directors when Matthew Kolb does not stand for re-election at the 2026 annual meeting. Nelson will receive standard non-employee director cash and equity compensation and enter into the company’s customary indemnification agreement.
The company highlighted Nelson’s extensive leadership experience across major health insurers and provider organizations and stated that his appointment aligns with a broader leadership refresh, including the recent naming of a new CEO and board chair.
Health Catalyst, Inc. announced leadership and workforce changes tied to its Project Nexus restructuring. The Board decided that Chief People Officer Linda Llewelyn will leave that role effective June 1, 2026 as the position is eliminated.
The company and Ms. Llewelyn anticipate a separation agreement and an independent contractor agreement under which she is expected to serve as a senior advisor from June 2, 2026 through September 1, 2026, receiving benefits available under the Executive Severance Plan in exchange for a general release of claims. As part of Project Nexus, the Board also authorized a global workforce reduction expected to cut approximately 9% of employees and remove about 100 additional open, budgeted headcount positions in the US and India.
Health Catalyst, Inc. outlines a transition arrangement with former Chief Executive Officer and principal executive officer Daniel Burton following his previously reported retirement effective February 12, 2026. To support a smooth handover, Burton will remain an employee as a strategic advisor through December 31, 2026.
Under the Transition Agreement dated March 31, 2026, he will receive an average monthly base salary of $10,000 starting March 1, 2026, in exchange for continued employment. He will forfeit all unvested restricted stock units and performance-based restricted stock units that could vest after March 2, 2026, and provide a general release of claims against the company.
Health Catalyst Inc ownership disclosure: The Vanguard Group filed Amendment No. 8 to report that it beneficially owns 0 shares of Common Stock, representing 0% of the class. The amendment explains an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries report separately.
First Light Asset Management and Mathew P. Arens filed an amended Schedule 13D for Health Catalyst, Inc. updating their ownership details. First Light is deemed to beneficially own 12,884,373 shares of common stock, representing 17.51% of the class. Arens reports beneficial ownership of 13,465,373 shares, or 18.3%, including 509,500 shares he owns individually and 71,500 shares held in joint accounts. The percentages are based on 73,586,183 shares of common stock outstanding as of March 5, 2026, as stated in the company’s Form 10-K. The filing notes that a First Light-managed fund has the right to receive dividends or sale proceeds from more than five percent of the outstanding shares and references recent transactions listed in an exhibit.